New hope for seniors with aggressive lymphoma: Four-Drug cocktail aims to spare chemo

NCT ID NCT07514169

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of four drugs (polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab) in 30 older patients (70+) newly diagnosed with large B-cell lymphoma who are too frail for standard chemo. The goal is to see if this gentler regimen can control the cancer and improve quality of life. Participants receive the drugs intravenously and orally over 12 cycles (21 days each).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab
What this could lead to: If successful, this could offer a gentler, effective treatment option for older patients with large B-cell lymphoma who cannot tolerate standard chemotherapy.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug combination may cause significant side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA (LBCL)

Contacts and locations

Locations

Ruijin Hospital
RECRUITING

Shanghai, 200020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.